The FDA issued a Complete Response Letter for Ascelia Pharma’s Orviglance NDA, requesting additional clinical data and product documentation before approval. The company plans regulatory discussions to identify an expedited path forward.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Ascelia Pharma has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Orviglance®, delaying the potential U.S. launch of the investigational magnetic resonance imaging (MRI) contrast agent for patients with severe kidney impairment.
According to the company, the FDA cannot approve the NDA in its current form and has requested additional clinical data along with product documentation before the application can proceed. The agency did not approve the submission based on the information currently available, requiring Ascelia Pharma to address the identified deficiencies before regulatory review can continue.
Orviglance Addresses an Unmet Need in Patients with Renal Impairment
Orviglance (mangoral) is an investigational oral contrast agent developed for liver MRI examinations in patients with impaired kidney function. This population has limited access to conventional gadolinium-based contrast agents because of the potential risk of nephrogenic systemic fibrosis in individuals with severe renal dysfunction.
By providing an oral alternative for liver imaging, Orviglance has been developed to improve diagnostic evaluation in patients who currently have restricted imaging options. The therapy targets a niche but clinically important population where safer contrast-enhanced imaging remains a significant unmet medical need.
FDA Requests Additional Clinical Evidence
While the FDA did not disclose specific deficiencies in the CRL, the agency requested additional clinical evidence and product-related documentation to support the NDA.
Ascelia Pharma stated that it is reviewing the agency’s feedback in detail and intends to request a Type A meeting with the FDA as soon as possible. Such meetings are typically held after major regulatory actions, including Complete Response Letters, to clarify deficiencies and discuss the most efficient path toward resubmission.
The company has not indicated whether additional clinical studies will be required or whether the requested information can be generated through existing or supplemental analyses.
Company Focuses on an Expedited Regulatory Path
Chief Executive Officer Magnus Corfitzen said the company remains confident in Orviglance despite the regulatory setback. He noted that the immediate priority is to engage with the FDA, understand the agency’s concerns, and identify the fastest route to address the outstanding requirements.
Management added that further updates will be provided once discussions with the FDA advance.
Path Forward
Ascelia Pharma plans to initiate regulatory discussions with the FDA through a Type A meeting to clarify the scope of the requested clinical data and documentation needed for a future NDA resubmission.
The company also confirmed that its current cash resources are expected to support operations into 2027. Alongside its regulatory strategy, management will evaluate potential cost-saving measures while continuing efforts to advance Orviglance toward a future approval decision.
Reference
Ascelia Pharma provides update on the Orviglance NDA – ASCELIA
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.